grant

Metabolic regulation of exosome biogenesis as a determinant of cancer cell metastasis.

Organization CORNELL UNIVERSITYLocation ITHACA, UNITED STATESPosted 1 Feb 2022Deadline 31 Jan 2027
NIHUS FederalResearch GrantFY20263-D3-Dimensional3D3D cell culture3D cultureAcetylationAffectAutomobile DrivingBiochemicalBiogenesisBiologic ModelsBiological ModelsBiologyBreast CancerBreast Cancer CellBreast Cancer ModelBreast MetastasisBreast tumor modelCancer BiologyCancersCathepsinsCell BodyCell Communication and SignalingCell SignalingCell surfaceCellsCellular AssayCharacteristicsChemicalsCuesData BasesDatabasesDeacetylaseDeacetylationDependenceDevelopmentDiseaseDisorderDown-RegulationEndosomesEnsureExhibitsGenerationsGlnGlutamineGoalsImmune EvasionImmune mediated therapyImmune responseImmunologically Directed TherapyImmunotherapyImpairmentIntermediary MetabolismIntracellular Communication and SignalingL-GlutamineLaboratoriesLungLung Respiratory SystemMaintenanceMalignant Breast NeoplasmMalignant CellMalignant NeoplasmsMalignant TumorMediatingMetabolicMetabolic ProcessesMetabolismMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModel SystemMonitorMultivesicular BodyMurineMusNatureNeoplasm MetastasisNon-Polyadenylated RNAOrganoidsOrigin of LifePlayProcessProductionProteinsQ LevoglutamideQ. LevoglutamideRNARNA Gene ProductsRNA-Binding ProteinsReagentReceptosomesRegulationResistanceRibonucleic AcidRoleSIRT1SIRT1 geneSecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingSilent Mating Type Information Regulator 2-like ProteinsSir2-like ProteinsSirtuin 1SirtuinsSystemTestingTherapeuticTranscriptTumor CellV-ATPaseV-type ATPaseWorkXenograft Modelaggressive breast cancerbiological signal transductionbreast cancer metastasisbreast tumor cellcancer cellcancer cell metabolismcancer metabolismcancer metastasiscancer progressioncell assaydata basedesigndesigningdevelopmentaldrivingexosomeexpectationextracellular vesiclesglutamine addictionglutamine dependenceglutamine dependent cancerhigh resolution imaginghost responseimmune evasiveimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseinsightmalignancymalignant breast tumormammary cancer modelmammary tumor modelmetastatic processmigrationmouse modelmultidisciplinarymurine modelneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachresistantsocial rolespheroidsthree dimensionalthree dimensional cell culturetraffickingtumortumor cell metabolismtumor cell metastasistumor growthtumor metabolismtumor progressionvacuolar ATPasevacuolar H+-ATPasevacuolar membrane H(+)-ATPasexenograft transplant modelxenotransplant model
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Abstract. The studies outlined in this proposal focus on the mechanisms by which aggressive breast cancer
cells generate large numbers of exosomes with unique cargo, together with a total secretome that

significantly enhances their potential for metastatic spread. They are based on exciting developments in

the cancer biology field which show that exosomes, a major class of extracellular vesicles (EVs), play

important roles in a number of aspects of cancer progression. These include the ability of exosomes to

confer tumor cells with the capability to show resistance to chemotherapeutic reagents as well as to immune

therapy, together with their roles in promoting metastatic spread. We recently discovered that the down-

regulation of SIRT1 by aggressive breast cancer cells has an important influence on the numbers of

exosomes that they generate, the nature of the exosome cargo, as well as the composition of their total

secretome. This is due to the NAD+-dependent deacetylase/deacylase Sirtuin (SIRT1) playing a key role in

maintaining normal lysosomal function through a novel mechanism that ensures the proper expression of a

major subunit of the vacuolar ATPae (v-ATPase). We also have recently found that the formation and

shedding of exosomes appear to be dependent on the elevations in glutamine metabolism characteristic of

breast cancer cells (i.e. their ‘glutamine addiction’). These findings now raise important questions regarding

how the dependence of aggressive breast cancer cells on glutamine metabolism influences and/or works

together with the down-regulation of SIRT1 expression/activation to regulate lysosomal function and

exosome biogenesis, thus producing a secretome that stimulates cancer cell invasiveness and helps drive

the metastatic process. The different laboratories participating in this proposal will take advantage of their

multi-disciplinary expertise in biochemical and chemical biology approaches in probing cancer cell

metabolism and exosome biogenesis, high-resolution imaging, 3D spheroid culture and tumor organoids,

and the use of mouse models, in probing three key aspects of the mechanisms driving breast cancer

metastasis. These are: 1) Examining the relationship between SIRT1 down-regulation, elevated glutamine

metabolism and the generation exosomes with unique cargo by aggressive breast cancer cells. 2)

Understanding how SIRT1 down-regulation impacts vacuolar ATPase expression to generate a secretome

capable of promoting cancer cell invasiveness. 3) Determining how SIRT1 expression/activity affects

exosome production, cell invasiveness and metastatic spread in breast cancer models. The expectation is

that these studies will lead to the identification of exciting new treatment strategies for the devastating effects

of aggressive breats cancers, and ultimately, for other metastatic diseases.

Grant Number: 5R01CA259195-05
NIH Institute/Center: NIH

Principal Investigator: MARC ANTONYAK

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →